 NEW YORK, May 4, 2021 PRNewswire -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI LSE: RENX NASDAQ: RNLX, announced today that COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test, was named as a finalist in the Pandemic Response category of the 2021 World Changing Ideas Awards. We are honored to be recognized by Fast Company for our Pandemic Response efforts, said Sara Barrington of Kantaro COVID-SeroKlir measures the presence and precise level of IgG antibodies against the receptor-binding domain and the full-length spike protein the same type of antibodies produced as part of the immune response to COVID-19 virus exposure or generated by a vaccine. 